Trial Profile

A Double-blind, Randomized, Placebo-Controlled Phase 2a Trial of GRI-0621 in Patients With Chronic Liver Disease

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 08 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tazarotene (Primary)
Indications Hepatitis B; Hepatitis C; Liver disorders; Non-alcoholic steatohepatitis
Focus Therapeutic Use
Acronyms GRI-201
Sponsors GRI Bio

Most Recent Events

01 Apr 2025 According to GRI Bio Media Release, company reported interim safety results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis
01 Apr 2025 Results published in the GRI Bio Media Release
21 Apr 2023 According to Vallon media release, data is expected in the Q2 of 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com